A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors
Completed
Conditions studied: Metastatic Breast Cancer
In brief
This is a retrospective cohort study to assess the real-world analysis of concomitant medication use among metastatic breast cancer patients treated with CDK4/6 inhibitors utilizing the US Optum research administrative claims database.
Key facts
- Study ID
- NCT05141240
- Run by
- Novartis Pharmaceuticals
- People needed
- 4650
- Starts
- 2020-04-15
- Expected to finish
- 2020-06-15
- Last updated by the study team
- 2021-12-16
Who can join
Age: 18 and older, up to 85. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Treated with CDK4/6i from 2015-02-01 to 2019-06-30
- ≥2 claims with a BC diagnosis recorded ≥30 days apart from the index date
- ≥2 claims with an mBC diagnosis, with a time interval between the first BC diagnosis date and the first mBC diagnosis date no longer than 30 days
- Female patients aged ≥18 years
- Continuous health plan enrollment for ≥3 months prior to the index date and ≥3 months post-index date
You may not qualify if…
- None
Where it is running
- Novartis Investigational site — East Hanover, New Jersey, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.